118 related articles for article (PubMed ID: 9413168)
1. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model.
Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA
Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth.
Abou-Issa HM; Alshafie GA; Curley RW; Wong MF; Clagett-Dame M; Repa JJ; Sikri V
Anticancer Res; 1999; 19(2A):999-1004. PubMed ID: 10368645
[TBL] [Abstract][Full Text] [Related]
3. In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent.
Abou-Issa H; Curley RW; Panigot MJ; Wilcox KA; Webb TE
Anticancer Res; 1993; 13(5A):1431-6. PubMed ID: 8239515
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth.
Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G
Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mammary tumor growth by a novel nontoxic retinoid: chemotherapeutic evaluation of a C-linked analog of 4-HPR-glucuronide.
Alshafie GA; Walker JR; Curley RW; Clagett-Dame M; Highland MA; Nieves NJ; Stonerock LA; Abou-Issa H
Anticancer Res; 2005; 25(3c):2391-8. PubMed ID: 16082771
[TBL] [Abstract][Full Text] [Related]
7. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
Alshafie GA; Harris RE; Robertson FM; Parrett ML; Ross M; Abou-Issa H
Anticancer Res; 1999; 19(4B):3031-6. PubMed ID: 10652588
[TBL] [Abstract][Full Text] [Related]
8. Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
Parrett ML; Abou-Issa HM; Alshafie G; Ross MS; Harris RE; Robertson FM
Anticancer Res; 1999; 19(6B):5079-85. PubMed ID: 10697514
[TBL] [Abstract][Full Text] [Related]
9. Effect of short-term administration of N-(4-hydroxyphenyl)-all-trans-retinamide on chemically induced mammary tumors.
Silverman J; Katayama S; Radok P; Levenstein MJ; Weisburger JH
Nutr Cancer; 1983; 4(3):186-91. PubMed ID: 6221232
[TBL] [Abstract][Full Text] [Related]
10. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
Walker JR; Alshafie G; Nieves N; Ahrens J; Clagett-Dame M; Abou-Issa H; Curley RW
Bioorg Med Chem; 2006 May; 14(9):3038-48. PubMed ID: 16412653
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
Webb TE; Abou-Issa H; Stromberg PC; Curley RC; Nguyen MH
Anticancer Res; 1993; 13(6A):2095-9. PubMed ID: 8297119
[TBL] [Abstract][Full Text] [Related]
13. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.
Abou-Issa H; Moeschberger M; el-Masry W; Tejwani S; Curley RW; Webb TE
Anticancer Res; 1995; 15(3):805-10. PubMed ID: 7645962
[TBL] [Abstract][Full Text] [Related]
14. Putative metabolites derived from dietary combinations of calcium glucarate and N-(4-hydroxyphenyl)retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12-dimethylbenz[a]anthracene.
Abou-Issa HM; Duruibe VA; Minton JP; Larroya S; Dwivedi C; Webb TE
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4181-4. PubMed ID: 2967969
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic evaluation of glucarate and N-(4-hydroxyphenyl)retinamide alone and in combination in the rat mammary tumor model.
Abou-Issa H; Webb TE; Minton JP; Moeschberger M
J Natl Cancer Inst; 1989 Dec; 81(23):1820-3. PubMed ID: 2531231
[TBL] [Abstract][Full Text] [Related]
16. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate.
Bhatnagar R; Abou-Issa H; Curley RW; Koolemans-Beynen A; Moeschberger ML; Webb TE
Biochem Pharmacol; 1991 May; 41(10):1471-7. PubMed ID: 1826840
[TBL] [Abstract][Full Text] [Related]
17. N-(4-hydroxyphenyl)all-trans-retinamide (4-HPR) high dose effect on DMBA-induced hamster oral cancer: a histomorphometric evaluation.
Lajolo C; Giuliani M; Sgambato A; Majorano E; Lucchese A; Capodiferro S; Favia G
Int J Oral Maxillofac Surg; 2008 Dec; 37(12):1133-40. PubMed ID: 18657950
[TBL] [Abstract][Full Text] [Related]
18. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Lewis KC; Hochadel JF
Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
[TBL] [Abstract][Full Text] [Related]
19. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
20. N-(4-hydroxyphenyl)retinamide prevents development of T-lymphomas in AKR/J mice.
Chan LN; Zhang S; Cloyd M; Chan TS
Anticancer Res; 1997; 17(1A):499-503. PubMed ID: 9066702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
